UBS AM
PGNX

UBS AM’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

UBS AM’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-53,343
Closed -$203K – 2577
2020
Q1 		$203K Sell
53,343
-3,119
-6% -$13.4K ﹤0.01% 2276
2019
Q4 		$287K Sell
56,462
-3,413
-6% -$18.1K ﹤0.01% 2380
2019
Q3 		$303K Buy
59,875
+12,864
+27% +$64.2K ﹤0.01% 2455
2019
Q2 		$290K Buy
47,011
+8,704
+23% +$42K ﹤0.01% 2426
2019
Q1 		$178K Hold
38,307
– – ﹤0.01% 2492
2018
Q4 		$161K Hold
38,307
– – ﹤0.01% 2454
2018
Q3 		$240K Hold
38,307
– – ﹤0.01% 2361
2018
Q2 		$308K Sell
38,307
-9,548
-20% -$72.9K ﹤0.01% 2292
2018
Q1 		$357K Buy
47,855
+8,306
+21% +$55.2K ﹤0.01% 2143
2017
Q4 		$235K Hold
39,549
– – ﹤0.01% 2229
2017
Q3 		$291K Buy
39,549
+825
+2% +$5.24K ﹤0.01% 2094
2017
Q2 		$263K Hold
38,724
– – ﹤0.01% 2086
2017
Q1 		$366K Buy
38,724
+11,300
+41% +$113K ﹤0.01% 1951
2016
Q4 		$237K Sell
27,424
-10,438
-28% -$77.2K ﹤0.01% 2037
2016
Q3 		$240K Buy
37,862
+3,762
+11% +$22.7K ﹤0.01% 2376
2016
Q2 		$144K Hold
34,100
– – ﹤0.01% 2533
2016
Q1 		$149K Hold
34,100
– – ﹤0.01% 2511
2015
Q4 		$209K Sell
34,100
-2,800
-8% -$18.4K ﹤0.01% 2517
2015
Q3 		$211K Buy
36,900
+2,800
+8% +$21.5K ﹤0.01% 2467
2015
Q2 		$254K Buy
+34,100
New +$206K ﹤0.01% 2462

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

UBS AM's PGNX Position: Q2 2020 in Review

UBS AM sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 53,343 shares — an estimated $203K sold.

UBS AM first reported a position in PGNX in Q2 2015 and held it in 20 quarters. The position peaked at $366K in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • UBS AM reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • UBS AM sold 53,343 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $203K.
  • UBS AM first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 20 quarters.
  • UBS AM's Progenics Pharmaceuticals Inc position peaked at $366K in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on UBS AM's 13F filing for Q2 2020, filed 14 Aug 2020.